CUDC-907 is a small molecule that inhibits PI3K (class Iα, β, and δ) and HDAC (class I and II), that showed a response rate of 64% in patients with DLBCL concurrent with MYC alteration (Oki et al., 2017). Here, PIK3CA is linked to diffuse large B-cell lymphoma.